Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Enanta Pharmaceutica (ENTA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,403,678
  • Shares Outstanding, K 19,420
  • Annual Sales, $ 206,630 K
  • Annual Income, $ 71,960 K
  • 36-Month Beta 0.91
  • Price/Sales 6.76
  • Price/Cash Flow 19.41
  • Price/Book 3.63

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 1.64
  • Number of Estimates 4
  • High Estimate 1.73
  • Low Estimate 1.49
  • Prior Year 0.78
  • Growth Rate Est. (year over year) +110.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
70.81 +2.08%
on 12/18/18
86.42 -16.36%
on 11/28/18
-8.92 (-10.99%)
since 11/16/18
3-Month
70.39 +2.69%
on 10/30/18
98.08 -26.31%
on 09/21/18
-18.65 (-20.51%)
since 09/18/18
52-Week
52.39 +37.97%
on 01/02/18
127.77 -43.43%
on 07/06/18
+15.55 (+27.41%)
since 12/18/17

Most Recent Stories

More News
Enanta Pharmaceuticals: Fiscal 4Q Earnings Snapshot

WATERTOWN, Mass. (AP) _ Enanta Pharmaceuticals Inc. (ENTA) on Monday reported fiscal fourth-quarter net income of $27.4 million.

ENTA : 72.28 (+0.46%)
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2018

--Royalty revenue for the quarter increased to $67.2 million

ENTA : 72.28 (+0.46%)
Enanta Pharmaceuticals (ENTA) Expected to Beat Earnings Estimates: Should You Buy?

Enanta Pharmaceuticals (ENTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ENTA : 72.28 (+0.46%)
Enanta Announces that AbbVie's MAVYRET(TM) (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Naive Hepatitis C Patients with Compensated Cirrhosis

--In cohort one, 100 percent of genotype 1, 2, 4, 5 and 6 treatment-naive chronic HCV patients with compensated cirrhosis achieved SVR12 with 8 weeks of MAVYRET per protocol analysis(1)

ENTA : 72.28 (+0.46%)
Why the Earnings Surprise Streak Could Continue for Enanta Pharmaceuticals (ENTA)

Enanta Pharmaceuticals (ENTA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

ENTA : 72.28 (+0.46%)
Enanta Pharmaceuticals to Host Conference Call on November 26 at 4:30 pm ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2018

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today...

ENTA : 72.28 (+0.46%)
Report: Developing Opportunities within Assured Guaranty, Potbelly, Enanta Pharmaceuticals, Seagate Technology, Ctrip.com International, and CyberArk Software -- Future Expectations, Projections Moving into 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Assured Guaranty Ltd. (NYSE:AGO),...

CTRP : 27.05 (-0.95%)
PBPB : 9.03 (-0.88%)
ENTA : 72.28 (+0.46%)
STX : 37.33 (-0.27%)
AGO : 37.07 (-0.46%)
CYBR : 71.21 (+1.92%)
Shares of ENTA Down 28.1% Since Downtrend Call on Shares

SmarTrend identified a Downtrend for Enanta Pharmaceu (NASDAQ:ENTA) on July 27th, 2018 at $106.78. In approximately 3 months, Enanta Pharmaceu has returned 28.09% as of today's recent price of $76.79....

ENTA : 72.28 (+0.46%)
Enanta Pharmaceuticals Announces Positive Phase 1 Results and Initiation of Phase 2a Clinical Study of EDP-938 for Respiratory Syncytial Virus

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today...

ENTA : 72.28 (+0.46%)
24.3% Return Seen to Date on SmarTrend Enanta Pharmaceu Call (ENTA)

SmarTrend identified a Downtrend for Enanta Pharmaceu (NASDAQ:ENTA) on July 27th, 2018 at $106.78. In approximately 3 months, Enanta Pharmaceu has returned 24.26% as of today's recent price of $80.87....

ENTA : 72.28 (+0.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade ENTA with:

Business Summary

Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown,...

See More

Key Turning Points

2nd Resistance Point 76.14
1st Resistance Point 74.21
Last Price 72.28
1st Support Level 70.58
2nd Support Level 68.88

See More

52-Week High 127.77
Fibonacci 61.8% 98.97
Fibonacci 50% 90.08
Fibonacci 38.2% 81.19
Last Price 72.28
52-Week Low 52.39

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar